What's Happening
To the Provider Community: We Hear You and Will Continue to Provide Solutions
Clarifying How to Use CPT® 96110, The Developmental Screening Test
CareFirst and CareFirst BlueChoice to Launch Temporary Card Effort
Claims and Billing
News for Standard and Basic Options of FEP
Appropriate Reporting of Electrical Stimulation Modalities
Timely Filing Limit Now 365 Days After Date of Service
Naltrexone Extended Release Injection Is Not A Covered Benefit
Hospitals/Institutions
Annual Update for Freestanding Ambulatory Surgery Centers
Pharmacy
FDA's Black Box Warnings to Appear on CareFirst Web Site
Health Care Policy
New Technologies Evaluated
Medical Policy Updates
Survey
PCPs Dissatisfied with Lack of Discharge Information
Provider Seminars
Practitioner and Staff Training Seminars
Hospital Seminars
Professional Seminars
Ancillary Seminars
Phone Numbers and Address
Phone Numbers and Address
Provider Representatives
Find Your Professional Provider Relations Representative
To the Provider Community: We Hear You and Will Continue to Provide Solutions
At CareFirst BlueCross BlueShield (CareFirst) and CareFirst BlueChoice, Inc. (CareFirst BlueChoice), we continue to look for easier and more efficient ways for you to interact with us. We have enhanced and expanded the capabilities of our FirstLine and BlueLine Voice Response Units (VRU) that enable you to get benefit information and responses to routine claims questions.
While we recognize that a provider may at first be apprehensive to use the VRU, we want to assure you that CareFirst and CareFirst BlueChoice stand behind the accuracy of the information provided and continually look for ways to make its usage more effective and efficient for our provider community.
Reasons to use the VRU:
- It saves time
- It gives accurate and consistent information
- It is available from 7 a.m. to 11:45 p.m. Monday through Friday
- No waiting on hold
- Complete multiple transactions within one call at your convenience
- Allows you more time to focus on other tasks
- More than 100 new benefit codes are available to providers through the FirstLine VRU
- Denial reasons are available by accessing claims denial
As part of CareFirst's Provider VRU - CareFirst Direct Campaign, effective Nov. 1, 2005, Provider Service Representatives at our CASCI, UCP and Red Run locations began to re-route provider calls back into the VRUs for calls that could otherwise be resolved through one of our self-service options.
Provider Service Representatives are available to assist you with:
- Accessing the VRU and providing step-by-step instructions on how to utilize the system, as needed
- Assistance with appeals
- Provide assistance with Administrative Services Only (ASO) accounts
- Assistance for out-of-area providers
- Materials to familiarize your staff on proper usage self-service options
- Assistance with difficult claims issues
The Provider Services Representatives do not need to verify the information on the VRU since these tools access the same databases available to CareFirst and CareFirst BlueChoice associates, and we stand behind these self-service options.
CareFirst and CareFirst BlueChoice are committed to creating initiatives to enhance our service and technology to make it easier for you and your staff, and to provide even more accurate eligibility, claims and benefit information. We invite you and your staff to try these self-help tools and experience how convenient and easy they are to use.
[top]
Clarifying How to Use CPT® 96110, The Developmental Screening Test
To all pediatricians, pediatric providers, family practitioners and practice managers:
In response to inquiries from pediatric practices, CareFirst BlueCross BlueShield (CareFirst) and CareFirst BlueChoice, Inc. (CareFirst BlueChoice) is clarifying the use of CPT® 96110.
Screening for developmental delays in motor, language and social interaction has been an important and integral part of monitoring children’s health for many years. Although there is a wide range of “normal” at any point in a child’s development, it is important to identify children who show signs of significant developmental delay so that more intensive efforts at diagnosis are initiated, followed by appropriate interventions. Although most children fall within the normal range, pediatricians are specially trained and highly experienced in the norms of developmental progress and in their ability to identify incipient delays in a child’s development.
Developmental assessment is a two-step process: firrst, a screening procedure to identify children in need of more indepth assessment; and second, developmental diagnosis, to better characterize the developmental problems and their significance in the context of a child’s biological, psychological and social strengths, and vulnerabilities.1
This developmental surveillance is an important technique used by pediatricians and family practitioners and is defined as a continuous process of skilled observations of a child during the provision of health care, including eliciting and responding to parental concerns, obtaining a relevant developmental history, accurate and informative observations of the child, and discussions with other relevant professionals.2
The American Academy of Pediatrics (AAP) recommends developmental/behavioral assessment of children at every preventive health visit, accomplished by history and appropriate examination, and if suspicious, by additional objective developmental testing.3 Consistent with this recommendation, CareFirst’s Preventative Services Guidelines include developmental assessment as part of each visit from birth through age 20.4
There are a number of formal and informal screening methods used by pediatricians and family practitioners to improve the sensitivity of screening methods. Pediatricians often use age-appropriate developmental checklists and parent questionnaires during preventive care visits as part of developmental surveillance. However, merely using a developmental checklist or administering a developmental history questionnaire is not the same as actually administering a timeintensive, structured developmental screening test. Such formal tests are carried out in a controlled environment by someone specially trained in the techniques of that particular test. The results and interpretation of such a developmental screening test must be comprehensive and include appropriate historical background, pertinent physical examination results, testing conditions, pertinent results of the test and recommendations for subsequent diagnostic and therapeutic measures.
CPT® 96110 is appropriate for the ensuing formalized testing of a child who has been found, through routine developmental surveillance, to be at risk for a significant delay in development. Therefore, it is not appropriate for pediatricians or family practitioners to submit a claim for CPT® 96110 for prescreening procedures done routinely during health maintenance.
In summary, CareFirst and CareFirst BlueChoice strongly support and encourage developmental screening services for children. However, that developmental screening is appropriately considered part of routine preventive health care, and thus is not paid as a separate service. A claim for CPT® 96110 should therefore only be submitted if the physician or another trained person under physician supervision and professionally licensed actually administers a formal, time-intensive structured developmental screening test, reports the results and interprets those results in light of the conditions of that particular child’s biological, psychological and social status.
- Nelson’s Textbook of Pediatrics, 16th edition, p. 61, 2000
- Developmental Surveillance and Screening of Infants and Young Children. American Academy of Pediatrics Committee on Children With Disabilities, Pediatrics 108:1, p.192-196, 2001
- Recommendations for Preventive Pediatric Health Care. American Academy of Pediatrics Committee on Practice and Ambulatory Medicine, Pediatrics 105: p. 645 – 646, 2000
- CareFirst Preventative Services
- Guidelines, http://www.carefirst.com/providers/attachments/BOK5079.pdf
Note: Current Procedural Terminology (CPT)® codes and descriptions are copyrights of the 1966 American Medical Association. All rights reserved.
[top]
CareFirst and CareFirst BlueChoice to Launch Temporary Card Effort
As part of an ongoing effort to make access to health care easier, CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. will launch a "Temporary ID Card" initiative this summer in which members can obtain and use a temporary identification card.
The initiative should help ease concerns for new members who have not yet received their permanent card as well as existing members who have lost their cards. Providers should be prepared to accept this paper copy as proof of health insurance.
[top]
News for Standard and Basic Options of FEP
The 2006 Federal Employees Program (FEP) for Standard and Basic Options have an acute rehabilitation benefit. Under the FEP Service Benefit Plan, this type of admission requires precertification by CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. Failure to do so will result in a $500 penalty. If the stay does not meet criteria of medical necessity, there will be no reimbursement. If the member is being discharged to an acute rehabilitation unit, you must call the hospital-assigned Utilization Review Nurse with the clinical information to support the medical necessity of the admission to facilitate the precertification.
[top]
Appropriate Reporting of Electrical Stimulation Modalities
A recent CareFirst BlueCross BlueShield (CareFirst) and CareFirst BlueChoice,
Inc. (CareFirst BlueChoice) study found
that a majority of claims were errantly reported with CPT 64550 instead of CPT
97014 or CPT 97032.
In several CPT® Assistant newsletter articles, CPT® describes the appropriate
reporting of codes 97014 and 97032. Refer to
the published reference material on these particular codes in the Summer 1995
issue and the April 2002 issue.
CareFirst and CareFirst BlueChoice consider services reported with CPT®
64550 experimental/investigational (E/I), as providing a home Transcutaneous
Electrical Nerve Stimulator (TENS) unit does not meet the evidence based CareFirst
Technology Assessment Criteria criteria #2, 3 and 5. For additional information,
refer to CareFirst and CareFirst BlueChoice Medical Policy 1.01.10, Transcutaneous
Electrical Nerve Stimulators (TENS), at www.carefirst.com > Providers &
Physicians > Medical Policies.
Note: Current Procedural Terminology (CPT)® codes and descriptions
are copyrights of the 1966 American Medical
Association. All rights reserved.
[top]
Timely Filing Limit Now 365 Days After Date of Service
In an effort to make doing business with us easier, CareFirst BlueCross BlueShield
and CareFirst BlueChoice, Inc. will
implement a consistent timely filing policy across all lines of business.
Effective July 1, 2006, providers will have a timely filing limit of 365 days
from the date of service for care rendered on or
after January 1, 2006. Each provider received formal notifi cation of this change,
which applies to Group Hospitalization
and Medical Services, Inc. and CareFirst of Maryland, Inc., collectively doing
business as CareFirst BlueCross BlueShield
and CareFirst BlueChoice, Inc.
This timely filing policy does not override any federal, state or locally mandated
timely filing periods for claims from
participating providers.
Please note that after the timely filing limit, or 365 days after the date
of service, providers are not eligible for
reimbursement by CareFirst and CareFirst BlueChoice. Also after the timely filing
limit, providers may not bill members
for covered services that were not submitted within the timely filing period.
We hope you find this change to the timely filing limit to be beneficial to
you and your office staff.
[top]
Naltrexone Extended Release Injection Is Not A Covered Benefit
CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. have determined that naltrexone (e.g., Vivitrol™), an extended-release injection for the treatment of alcohol dependence, will not be a covered benefit, effective immediately. There is no scientific evidence that this new formulation improves outcomes.
If you have questions, please contact your Provider Services representative.
[top]
Annual Update for Freestanding Ambulatory Surgery Centers
Effective
March 1, 2006, CareFirst BlueCross BlueShield (CareFirst) and CareFirst BlueChoice,
Inc. (CareFirst BlueChoice) formulated and implemented the annual update for
all participating Freestanding Ambulatory Surgery Centers (ASC). Services rendered
as a Participating Freestanding ASC Provider with CareFirst and CareFirst BlueChoice
on and after March 1, 2006 will be governed by the agreement, as amended, effective
that date. The purpose of the amendments are as follows:
- Updated the CPT®-4 Codes to reflect 2006 additions and deletions made
by the American Medical Association (AMA).
- Incorporated changes made by Medicare to the listing of ambulatory surgery
codes.
- Deleted CPT® Code 50590 from Attachment A-1. Approved ASC Procedure
Codes and Payment Groups. Corporation will be contracting directly with Lithotripsy
Providers for all Lithotripsy Services.
- Added to the list of surgeries are those eligible for payment in ASC CPTCodes
that have not yet been added by Medicare. The additional CPT® Codes eligible
for payment are: 15170, 15171, 15175, 15176, 50382, 50384, 50387 and 50389.
- Clarified language that payments for Extraordinary Supplies, Implants and
Prosthetics are equal to 100 percent of the Medicare Maryland DMERC rates
for 2006. Attachment A-2 reflects these amounts and specifies related quantities.
- All future annual reviews and updates performed by CareFirst and CareFirst
BlueChoice shall be changed from March 1 of each calendar year to May 1 of
each calendar year, effective May 1, 2007.
Note: Current Procedural Terminology (CPT)® codes and descriptions
are copyrights of the 1966 American Medical Association. All rights reserved.
[top]
FDA's Black Box Warnings to Appear on CareFirst Web Site
As part of the CareFirst BlueCross BlueShield (CareFirst) and CareFirst BlueChoice, Inc. (CareFirst BlueChoice) patient safety initiative, Black Box Warnings issued by the Food and Drug Administration (FDA) will be posted on the CareFirst Web site, www.carefirst.com, as they become available.
Black Box Warnings are the FDA’s strongest warnings and are required to be placed on prescription drug labels to indicate that the product may cause serious adverse effects. The warning means clinical studies or serious animal toxicity indicate the drug carries “Special problems, particularly those that may lead to death or serious injury,” according to the FDA. The FDA requires some prescription drugs to include a Medication Safety Guide each time the medication is dispensed.
To access the warnings on the CareFirst Web site, click here. Notice of Black Box Warnings are also available via e-mail to those who are registered to receive e-mail from CareFirst and CareFirst BlueChoice.
[top]
New Technologies Evaluated
Our Technology Assessment Unit evaluates new and existing technologies to apply
to our local indemnity and managed care benefit plans. The unit relies on current
medical literature, local expert consultants and physicians to determine whether
those technologies meet CareFirst BlueCross BlueShield (CareFirst) and CareFirst
BlueChoice, Inc. (CareFirst BlueChoice) criteria for coverage. Policies for non-local
accounts like NASCO and FEP may differ from our local determinations. Please verify
member eligibility and benefits prior to rendering services via BlueLine, FirstLine
or CareFirst Direct. The Technology Assessment unit recently made the following
determinations:
| New Technology |
Description |
CareFirst Determination |
| Mechanical embolus removal (MERCI®)
system for acute ischemic stroke |
Removal of a thrombus or embolus from
the cerebral circulation by means of a
corkscrew shaped wire catheter |
Considered experimental /
investigational by CareFirst and CareFirst
BlueChoice.
CPT® reporting code 37799
|
| Percutaneous carotid artery angioplasty
and stent, with or without distal embolic
protection, for carotid stenosis |
A percutaneous alternative to carotid
endarterectomy to widen the lumen of
the carotid artery and improve cerebral
circulation |
Considered experimental /
investigational by CareFirst and CareFirst
BlueChoice.
CPT® reporting codes 37215, 37216, 0075T, 0076T
|
| Extracorporeal shock wave therapy
(ESWT) for soft-tissue infl ammation
for areas other than the foot, i.e.
epicondylitis, capsulitis, tendonitis |
Application of shock wave energy
to alleviate symptoms in disorders
including, but not limited to,
epicondylitis, tendonitis of the elbow,
adhesive capsulitis of the shoulder |
Considered experimental /
investigational by CareFirst and CareFirst
BlueChoice.
CPT® reporting code 0019T, 0101T, 0102T
|
| Arthroscopic thermal capsular shrinkage
for chronic unstable shoulder |
The use of heat energy, applied with a
thermal catheter, to shrink connective
tissue of the shoulder joint and reduce
dislocations |
Considered experimental /
investigational by CareFirst and CareFirst
BlueChoice.
CPT® reporting code 23929
|
Note: Current Procedural Terminology (CPT)® codes and descriptions
only are copyright of the 1966 American Medical Association. All rights reserved.
Category III CPT® Reporting Codes Effective Jan. 1, 2006
| New Code |
Determination |
| 0120T |
Experimental / investigational |
| 0123T |
Experimental / investigational |
| 0124T |
Experimental / investigational |
| 0126T |
Experimental / investigational |
| 0130T |
Not a covered benefit |
| 0133T |
Experimental / investigational. No longer applicable, product withdrawn
from distribution by manufacturer |
| 0135T |
Experimental / investigational |
| 0137T |
Equivalent to 55700 |
| 0140T |
Experimental / investigational, currently in clinical trials |
| 0141T |
Experimental / investigational |
| 0142T |
Experimental / investigational |
| 0143T |
Experimental / investigational |
| 0144T |
Experimental / investigational |
| 0145T |
Experimental / investigational |
| 0146T |
Experimental / investigational |
| 0147T |
Experimental / investigational |
| 0148T |
Experimental / investigational |
| 0149T |
Experimental / investigational |
| 0150T |
Experimental / investigational |
| +0152T |
Experimental / investigational |
| +0153T |
Experimental / investigational |
| +0154T |
Experimental / investigational |
Note: Current Procedural Terminology (CPT)® codes and descriptions
only are copyright of the 1966 American Medical Association. All rights reserved.
Category III CPT® Reporting Codes Effective July 1, 2006
| New Code |
Determination |
| 0155T |
Experimental / investigational |
| 0156T |
Experimental / investigational |
| 0157T |
Experimental / investigational |
| 0158T |
Experimental / investigational |
| 0159T |
Included in the benefit for the primary procedure |
| 0160T |
Experimental / investigational. |
| 0161T |
Experimental / investigational |
Note: Current Procedural Terminology (CPT)® codes and descriptions
only are copyright of the 1966 American Medical Association. All rights reserved.
[top]
Medical Policy Updates
The Health Care Policy Department reviews medical policies and operating procedures
on a consistent basis as new,
evidence-based information becomes available regarding advances in new or emerging
technologies, as well as current
technologies, procedures and services.
The table below is a new guide designed to provide updates on any changes to
existing or new local policies and procedures identifying our review process.
Each local policy or procedure listed includes a brief description of its status,
select reporting instructions and effective dates. Policies for non-local accounts
such as NASCO and FEP may differ from our local determinations. Please verify
member eligibility and benefits prior to rendering services via BlueLine, FirstLine
or CareFirst Direct.
| Medical Policy and/or Procedure |
Actions, Comments and Reporting Guidelines |
Policy Status and Effective Date |
1.01.06
Ultrasound Accelerated Fracture Healing Device |
Description revised. Under Policy, further defined that these devices
should be used in skeletally mature individuals. Under Policy Guidelines,
a Rationale statement was added. |
Periodic review and update.
Effective 5/26/06
|
1.01.18
Neuromuscular Electrical Stimulation (NMES) |
Neuromuscular electrical stimulation devices are considered
medically necessary for the treatment of disuse atrophy. See policy
for experimental/ investigational indications. This policy only
addresses NMES devices as durable medical equipment. Report
with HCPCS code E0745. |
New Policy.
Effective 4/24/06
|
1.02.02
Elemental Nutrition for Treatment of Malabsorption Disorders |
Under Policy Guidelines, a Rationale statement was added. Under
Benefit Applications, Benefits are not provided for items or
supplies, as determined by the Plan, that can be purchased without
a prescription, unless otherwise a covered service. Most elemental
formulas are available without a prescription. Check the members
contract for benefits. |
Periodic review and update.
Effective 5/2/06
|
2.01.08
Rhinomanometry and Acoustic Rhinometry |
Under Policy Guidelines, a Rationale statement was added. |
Periodic review and update.
Effective 5/26/06
|
2.01.38A
Diagnostic Eye Procedures with Companion Table |
Within attached companion table, under unilateral procedures, for both
eyes, report on two separate lines, or on two separate lines with a RT (right)
or LT (left) modifier. Providers should no longer report these services
with a -50 modifier on one line with a frequency of two in order to ensure
correct adjudication of their claims. |
Periodic review and update.
Effective 6/30/06
|
2.01.48A
Acupuncture |
Under Benefit Applications, clarified second statement, Benefits
are provided, with or without electrical stimulation, for the initial
15 minutes of personal one-on-one contact with the patient; and
each additional 15 minutes of personal one-on-one contact with the
patient provided there is re-insertion of the needle(s). |
Periodic review and update.
Effective 5/2/06
|
2.01.49
Xenon Chloride Excimer Laser Therapy for Treatment of Psoriasis |
Title changed from Excimer Laser Treatment for Psoriasis. Under
Policy statement, Xenon Chloride excimer laser ultraviolet B (UVB)
treatment is considered medically necessary for treatment of mild
to moderate plaque psoriasis. Xenon Chloride excimer laser UVB
treatment is experimental / investigational for all other conditions.
Under Policy Guidelines, a Rationale statement was added. |
Periodic review and update.
Effective 5/22/06
|
2.02.03
Thoracic Electrical Bioimpedance Measurement |
Under Policy Guidelines, a Rationale statement was added. Report
using CPT® 93701. |
Periodic review and update.
Effective 5/2/06
|
4.01.06A
Global Maternity Care |
Under Benefit Applications, when maternity benefits are provided
under the members contract, additional benefits are provided
for diagnostic and therapeutic services not covered in the global
maternity care allowance. Review Operating Procedure for
examples. |
Periodic review and update.
Effective 5/22/06
|
4.02.08
Recurrent Pregnancy Loss (Recurrent Spontaneous Abortion) |
Under Policy statement added hysterosonography/
sonohysterography to the medically necessary diagnostic tests and
procedures for recurrent pregnancy loss. Added Embryo toxicity
assay (ETA) to the list of experimental / investigation diagnostic
tests. Under Policy Guidelines, a Rationale statement was added. |
Periodic review and update.
Effective 5/22/06
|
5.01.03
Colony Stimulating Factor |
Please review policy for revised indications for colony stimulating
factors. Under Policy Guidelines, added a Rationale statement. |
Periodic review and update.
Effective 4/19/06
|
6.01.22
Magnetic Resonance Imaging (MRI) of the Breast |
Under Policy statement added MRI of the breast is considered
medically necessary for patients known to be a high genetic risk for
breast cancer with certain indications. MRI of the breast for routine
screening purposes is considered experimental / investigational.
For routine screening of the population, mammography is still
considered the standard testing modality for the early detection of
breast cancer. See the policy for further details.
|
Periodic review and update.
Effective 4/19/06
|
6.01.37
Selective Internal Radiation Therapy for Malignant Hepatic Tumors |
Selective internal radiation therapy (SIRT) using yttrium-
90 impregnated microspheres is considered experimental /
investigational. |
New Policy.
Effective 4/20/06
|
7.01.29
Thermal Capsulorrhaphy for Joint Instability |
Title changed from Arthroscopic Thermocapsular Shrinkage for Joint
Capsule. Policy revised to change arthroscopic thermocapsular
shrinkage of the shoulder joint (thermal capsulorrhaphy) from
medically necessary to experimental / investigational. Thermal
capsulorrhaphy for all other joints remains experimental /
investigational. |
Periodic review and update.
Effective 8/21/06
|
7.01.41
Treatments for Urinary Incontinence |
Under Policy, periurethal injection of carbon-coated sphere or
copolymers to treat stress incontinence is considered medically
necessary. Periurethal injection of carbon coated spheres or
copolymers to treat urge incontinence is considered experimental /
investigational. Under Policy Guidelines, a Rationale statement was
added. |
Periodic review and update.
Effective 5/22/06
|
7.01.73
Radiofrequency Ablation of Malignant Tumors of the Liver |
Under Policy Guidelines, a Rationale statement was added.
Radiofrequency ablation (RFA) of malignant tumors of the liver
is considered medically necessary as a palliative treatment in
those patients whose lesions are non-resectable and who have a
relatively low tumor burden. |
Periodic review and update.
Effective 4/24/06
|
7.01.77
Stapled Hemorrhoidectomy |
Under Policy Guidelines, a Rationale statement was added. Policy
to be archived.
|
Periodic review and update. Policy archived.
Effective 5/22/06
|
7.01.86
Carotid Artery Angioplasty and Stenting |
Description revised. Under Policy Guidelines, a Rationale statement
was added. Percutaneous carotid artery angioplasty and stent
placement remains experimental / investigational. |
Periodic review and update.
Effective 5/26/06
|
7.01.91
Minimally Invasive Intervertebral Disc Decompression procedures for lower
back pain |
Minimally invasive intervertebral disc decompression procedures
are considered experimental / investigational. |
New Policy.
Effective 4/20/06
|
7.01.92
Intraspinous Vertebral Decompression Implantation for Spinal Stenosis |
Intraspinous implants for symptomatic spinal stenosis are
considered experimental / investigational. |
New Policy.
Effective 4/20/06
|
7.01.93
Total Ankle Arthroplasty/ Replacement |
Total ankle arthroplasty / total ankle replacement is considered
experimental/ investigational. |
New Policy.
Effective 8/21/06
|
10.01.01A
Clinical Trials Mandates, Maryland and Virginia |
Operating Procedure is compliant with the mandated benefit. For
those contracts which do not follow state mandates, benefits are
provided only if included in specific contract language. |
Periodic review and update.
Effective 5/2/06
|
11.01.01
Tumor Markers |
Under the Policy section, the bulleted list of tumor markers is
considered medically necessary when monitoring treatment
response and possible cancer recurrence. Under Policy Guidelines,
added PSA can also be performed for screening of prostate
cancer. A Rationale statement was also added.
|
Periodic review and update.
Effective 4/20/06
|
POLICIES UNCHANGED FROM LAST REVIEW
1.02.03 Enteral Nutrition Therapy
1.04.01 Prosthetics
Note: Current Procedural Terminology (CPT)® codes and descriptions
are copyrights of the 1966 American Medical Association.
All rights reserved.
[top]
PCPs Dissatisfied with Lack of Discharge Information
A
recent survey by the CareFirst BlueCross BlueShield and CareFirst BlueChoice,
Inc. Quality Improvement department found that many primary care physicians
(PCPs) are dissatisfied with the lack of discharge information from acute and
skilled nursing facilities.
To facilitate improved continuity of care, PCPs are encouraged to instruct
their patients to request the attending physician and/or facility to forward
a copy of their discharge summary to their PCP.
PCPs may also request discharge information regarding an Emergency Room visit
and/or any inpatient admission directly from a hospital or skilled nursing facility.
[top]
Practitioner and Staff Training Seminars
CareFirst BlueCross BlueShield (CareFirst) and CareFirst BlueChoice, Inc. (CareFirst BlueChoice) offer half-day seminars designed to familiarize professional and institutional providers and office staff with CareFirst and CareFirst BlueChoice policy and provider-oriented procedures. We offer a variety of seminars to appeal to the needs of our versatile provider community. These seminar types are listed below, accompanied by a brief description and its identification code to assist in the selection of the appropriate seminar to meet your needs.
B to B - Back to Basics - designed to introduce professional providers to CareFirst’s and CareFirst BlueChoice’s full portfolio of products, claims submission procedures, coordination of benefits, administrative policies, quality improvement, the latest information on BlueCard and more. This seminar is an excellent “new provider staff” or “provider refresher” tool. Attendance will accredit primary care providers for CareFirst BlueChoice, Inc. Primary Care Physician Recognition Program.
Hospital Quarterly - designed to provide hospital staff with updated information on changes at CareFirst and CareFirst BlueChoice and may include special presentations on select topics.
Ancillary - designed to provide ancillary providers (Dialysis, SNF, DME, HIT, ASC, Hospice, Home Health and Mental Health) with updated information on changes at CareFirst and CareFirst BlueChoice and may include special presentations on select topics.
eFocus - designed to provide professional and institutional providers with information related to electronic claims solutions that are available through electronic claims submission, CareFirst Direct and www.carefirst.com. Representatives will also provide a high-level presentation on basic and updated CareFirst products and procedures. Attendance will accredit primary care providers for CareFirst BlueChoice, Inc. Primary Care Physician Recognition Program.
eoh - eSystems Open House - designed to provide professional and institutional providers with more in-depth information on electronic claims solutions. This event will be a larger and more detailed event than our Mini Fairs and will be presented on Oct. 4, 2006 at the Columbia Hilton in Columbia, Md. More details and enrollment will be made available during the 2nd quarter of 2006.
Update - “Update Me” Seminars - designed to update professional and institutional providers about CareFirst and CareFirst BlueChoice changes. As a result of their popularity with our provider community in 2005, CareFirst “Update Me” seminars will return in 2006. Locations, dates and times will be announced later in the year and will take place during the 4th quarter of 2006. Attendance will accredit primary care providers for CareFirst BlueChoice, Inc. Primary Care Physician Recognition Program.
To register for any of these seminars, visit the Providers & Physicians section of www.carefirst.com for a full list of 2006 seminars and select “Register for a Seminar” in the Solution Center. If you do not have internet access, call the Provider Seminar Registration Line at 877-269-2219. Below is a list of upcoming seminars. Please note: Sign-in for seminars begins 15 minutes prior to the scheduled start time.
[top]
Hospital Seminars
| Date and Time
| Location |
Room |
Tuesday, September 26, 2006
10 a.m. to 1 p.m.
Hospital Quarterly |
Arlington Hilton and Towers
950 North Stafford St.
Arlington, Va. 22201 |
Gallery Ball Room |
|
[top]
Professional Seminars
| Date and Time |
Location |
Room |
Wednesday, September 13, 2006
10 a.m. to 1 p.m.
B to B |
Sibley Memorial Hospital
5255 Loughboro Road
Washington, D.C. 20016 |
Renanissance Conference Room |
Thursday, June 29, 2006
1 p.m. to 4 p.m.
B to B |
Upper Chesapeake Medical Ctr.
500 Upper Chesapeake Drive
Bel Air, Md. 21014 |
Chesapeake Conference Room |
|
[top]
Ancillary Seminars
| Date and Time
| Location |
Room |
Wednesday, June 21, 2006
10 a.m. to 1 p.m.
Home Health |
CareFirst BlueCross BlueShield
6731 Columbia Gateway Drive
Columbia, Md. 21046 |
Redwood Room |
Tuesday, June 27, 2006
10 a.m. to 1 p.m.
Mental Health
|
Anne Arundel Medical Center
2002 Medical Parkway
Annapolis, Md. 21401 |
Room 250A |
Tuesday, July 11, 2006
10 a.m. to 1 p.m.
DME |
Holiday Inn Express
241 Railway Lane
Hagerstown, Md. 21740 |
Conference Room |
Wednesday, July 26, 2006
9 a.m. to noon
ASC |
Easton Memorial Hospital
219 S. Washington St.
Easton, Md. 21601 |
Health Education Center, Rooms C & D |
Wednesday, July 26, 2006
1 p.m. to 4 p.m.
SNF |
Easton Memorial Hospital
219 S. Washington St.
Easton, Md. 21601 |
Health Education Center, Rooms C & D |
Tuesday, August 1, 2006
1 p.m. to 4 p.m.
ASC |
Holiday Inn Express
241 Railway Lane
Hagerstown, Md. 21740 |
Conference Room |
|
[top]
Phone Numbers and Address
See Where to File a Claim (Phone Numbers)
[top]
Find Your Professional Provider Relations Representative
Not sure who your provider representative is or what number to call to reach him/her?
[top]
|